Aprea Therapeutics, Inc. (APRE) earnings
APRE earnings moved a median of -3.10% by the close. Quarterly and annual APRE reports and results, each read against the price at its own news timestamp. Back to the APRE overview →
21 measured APRE earnings events.
Where these APRE earnings landedvs 19 measured APRE earnings reactions
| Middle 50% of APRE earnings reactions | -6.65% to +1.79% |
|---|---|
| Median reaction (to close) | -3.10% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 APRE earnings events with a measured close landed between -6.65% and +1.79%; 32% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Aprea Therapeutics Announces Second Quarter 2026 Financial Results | Press release | -10.37% | -12.44% | |
| Form 10-Q Aprea Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -10.37% | -12.44% | |
| Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Press release | — | -9.13% | |
| Form 10-Q Aprea Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | — | -9.13% | |
| Form 10-K Aprea Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -7.91% | -9.99% | |
| Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update | Press release | +0.00% | -1.56% | |
| Form 10-Q Aprea Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -1.56% | |
| Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update | Press release | — | — | |
| Form 10-Q Aprea Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | — | — | |
| Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update | Press release | +10.00% | +2.00% | |
| Form 10-Q Aprea Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +10.00% | +2.00% | |
| Form 10-K Aprea Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.21% | -3.10% | |
| Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | +0.00% | +1.79% | |
| Form 10-Q Aprea Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +1.79% | |
| Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +0.00% | -4.17% | |
| Form 10-Q Aprea Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -4.17% | |
| Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update | Press release | +0.90% | +6.32% | |
| Form 10-Q Aprea Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.90% | +6.32% | |
| Form 10-K Aprea Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -1.99% | |
| Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update | Press release | — | -4.00% | |
| Form 10-Q Aprea Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | — | -4.00% |
Keep exploring
More APRE: analyst actions → · SEC filings → · APRE overview →
Other Industrials names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Embraer S.A. (ERJ) | 222 | +0.13% | 59% |
| Triumph Group, Inc. (TGI) | 222 | 0.00% | 48% |
| LEGACY ACQUISTION CORP (LGC) | 221 | 0.00% | 16% |
| TOMI Environmental Solutions, Inc. (TOMZ) | 220 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.